HOME >> BIOLOGY >> NEWS
Could estriol be the elixir for MS?

It has long been common knowledge that pregnant women with multiple sclerosis (MS) experience a sharp drop in the disease's symptoms during the course of their pregnancy.

Some years back, Dr. Rhonda Voskuhl, director of UCLA's Multiple Sclerosis Program, and her colleagues discovered the cause. They found that a female sex hormone called estriol, which is produced during pregnancy, was responsible for the suppression. Four years ago, Voskuhl followed that discovery with a pilot study in which 10 non-pregnant women with MS were given estriol, yielding what she described as "pretty remarkable" results an 80 percent drop in inflammatory lesions in the brain, a hallmark of the disease.

This month, Voskuhl begins a much larger trial of estriol, one that will involve 150 patients at multiple locations over the next two years. The prospects, she said, are exciting.

Multiple sclerosis is an autoimmune disease of the central nervous system that attacks the tissue surrounding the brain's nerve fibers. This tissue, called myelin, can be thought of as the insulation wrapped around an electrical wire. When the myelin is damaged, the nerve's ability to send signals to and from the brain is interfered with, resulting in symptoms common to MS, including problems with balance, memory, vision loss and more.

Currently, anti-inflammatory drugs used to treat MS lessen the symptoms and slow the progression of the disease. But they must be given by injection daily, weekly or monthly depending on the drug and are expensive, costing between $12,000 to $24,000 a year.

Estriol is a hormone produced by the placenta that is virtually undetectable until pregnancy, when it progressively increases. It is thought that its role is to suppress a woman's immune system when she is pregnant, so that the fetus will not be seen by the body as a foreign "invader."

"The beauty of estriol is that it can be given as a pill, not a shot, and
'"/>

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles
22-Mar-2007


Page: 1 2

Related biology news :

1. Could fungal collection hold the key to new life-saving drugs?
2. Could USA presidential DNA trail reveal Middle-Eastern origins?
3. Quantum dots reviewed -- Could these nanoparticles hold the cure to cancer?
4. Could a pint of cider help keep the doctor away?
5. Friend or foe: Could a protein linked to Alzheimers be related to vision loss in seniors?
6. Could plain soap and probiotics beat hospital bugs?
7. Could better mangrove habitats have spared lives in the 2004 tsunami?
8. Recurrent miscarriages: Could prednisolone reduce the occurrence of this distressing condition?
9. Could microbes solve Russias chemical weapons conundrum?
10. Could schizophrenia arise from a single defect?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Could estriol the elixir for

(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , ... problems, is pleased to announce their ranking as one of the top 5000 companies ... fastest-growing private companies across the nation. , “It is truly an honor to be ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company ... in a Phase I study of BHV-0223, a ... application (IND) regarding BHV-0223 and recently obtained clearance ... to proceed with human testing. Portage holds 54% ...
(Date:8/27/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that executives from the company will ... September.  , Pedro Lichtinger , ... 17th Annual Global Investment Conference on Wednesday, September 10, ... Hotel in New York City . ...
(Date:8/27/2015)... HUYA Bioscience International (HUYA) today announced the sponsorship ... of HTLV-1, held this week at the University of ... Society is to promote research on HTLV-1 and HTLV-1-associated ... and research related to these fields to advance science, ... proud to support this prestigious conference," said Mireille ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
Cached News: